… is a tyrosine kinase inhibitor 30-fold more potent than imatinib against BCR-ABL kinase.
Nilotinib is active against a wide range of imatinib-resistant BCR-ABL mutant isoforms, except …

… of imatinib as … of imatinib-resistant mutations. Here, we review the current knowledge about
the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib…

… Nilotinib (Tasigna; Novartis Pharmaceuticals) is a second-generation TKI that was … against
BCR–ABL1 mutations associated with resistance to imatinib. Compared with imatinib, nilotinib …

… Note that imatinib and nilotinib bind the inactive state of Abl in a similar manner, including
a hydrogen bond with the main chain amide of interlobe residue Met318, a hydrogen bond …

… Our findings suggest that nilotinib might be superior to imatinib mesylate in terms of the
development of resistance. However, our study indicates that clinical resistance to …

… did patients randomized to continue imatinib. Per the study protocol, patients in the imatinib
arm with detectable BCR-ABL1 at 24 months were allowed to cross over to nilotinib. Here we …

… of imatinib-resistant or imatinib-intolerant disease. In the current study, we generated
nilotinib-… We also tested the effect of imatinib on nilotinib-resistant cell lines, showing that the …

… inhibitors, which minimize the number of residual BCR-ABL + cells capable of developing
resistance and which maintain activity against imatinib mesylate-resistant BCR-ABL mutants. …

… 400 mg twice daily vs imatinib). At 24 months… nilotinib groups than in the imatinib group (five
with nilotinib 300 mg twice daily, three with nilotinib 400 mg twice daily, and ten with imatinib)…

… molecular response (EMR; BCR-ABL ≤10% on the international scale [BCR-ABL IS ] at 3
or … with nilotinib or imatinib based on 4 years of follow up in Evaluating Nilotinib Efficacy and …